Dexamethasone, Neomycin, Thiabendazole

Verify with FDA CVM →

102 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
102
Total Reports
2
Deaths Reported
200.0%
Death Rate

Active Ingredients

Dexamethasone, Neomycin, Thiabendazole

Administration Routes

Auricular (Otic)OphthalmicTopicalUnknownOral

Species Affected

Dog 53
Cat 28
Human 18
Unknown 3

Most Affected Breeds

Domestic (unspecified) 22
Unknown 21
Crossbred Canine/dog 13
Poodle (unspecified) 7
Cat (unknown) 4
Maltese 3
Retriever - Labrador 3
Pug 3
Terrier - Yorkshire 2
Chihuahua 2

Most Reported Reactions

Accidental exposure 20
Deafness 19
Unclassifiable adverse event 18
Eye irritation 14
Anorexia 10
Eye pain 10
Pinnal irritation 9
Depression 8
Vomiting 5
Diarrhoea 5
Pinnal erythema 5
Elevated alanine aminotransferase (ALT) 5

Outcome Breakdown

Died
2 (100.0%)

Data Summary

Metric Value
Total adverse event reports 102
Reports involving death 2
Case-fatality rate (reported events) 200.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dexamethasone, Neomycin, Thiabendazole Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 102 adverse event reports referencing Dexamethasone, Neomycin, Thiabendazole, including 2 reports in which the animal died — a 200.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Dexamethasone, Neomycin, Thiabendazole. Reported administration routes include Auricular (Otic), Ophthalmic, Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dexamethasone, Neomycin, Thiabendazole reports are Dog (53 reports), Cat (28 reports), Human (18 reports), with Dog accounting for the largest share. Within those species, Domestic (unspecified) (22), Unknown (21), Crossbred Canine/dog (13) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dexamethasone, Neomycin, Thiabendazole are Accidental exposure (20), Deafness (19), Unclassifiable adverse event (18), Eye irritation (14). Of the 2 reports with a coded outcome, Died is the leading category at 100.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dexamethasone, Neomycin, Thiabendazole.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial